sajor2000/methodsmith / plugins/methodsmith/skills/method-checklist
method-checklist
VerifiedSelects EQUATOR reporting guidelines (CONSORT, STROBE, RECORD, PRISMA, TRIPOD+AI, TARGET, STARD, CLAIM) for a study. Use when the user asks which reporting checklist applies.
| File | Kind | Size |
|---|---|---|
| SKILL.md | skill md | 9.9 KB |
| references/checklist-snippets/CONSORT.md | markdown | 5.7 KB |
| references/checklist-snippets/DECIDE-AI.md | markdown | 979 B |
| references/checklist-snippets/PRISMA-P.md | markdown | 805 B |
| references/checklist-snippets/SPIRIT.md | markdown | 10.0 KB |
| references/checklist-snippets/STROBE.md | markdown | 4.5 KB |
| references/checklist-snippets/TRIPOD-AI.md | markdown | 8.0 KB |
| references/checklist-snippets/TRIPOD-LLM.md | markdown | 858 B |
| references/evidence-access.md | markdown | 2.2 KB |
| references/routing-map.md | markdown | 11.7 KB |
references/checklist-snippets/CONSORT.md
View on GitHub# CONSORT 2025 Checklist (Reporting of Randomized Controlled Trials)
Current CONSORT core for randomized trials: 30 numbered items (42 rows with lettered sub-items) in six sections, including the new Open Science section. Item numbers and wording mirror the CONSORT 2025 checklist that `method-review` validates against at review time, so the plan-time placeholder and the review-time check use the same items. Fill each row as the SAP and manuscript develop. For specialized RCT designs, layer on the relevant extension (Cluster, Adaptive, N-of-1, AI). CONSORT 2025 supersedes CONSORT 2010 (25 items); do not reuse the old item numbers.
**Current primary reference:** Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. doi:10.1136/bmj-2024-081123. PMID: 40228833. Published simultaneously in BMJ, JAMA, Lancet, Nature Medicine, and PLOS Medicine.
**Source table:** CONSORT 2025 Table 1, PMC11995449 (read as `full_text`).
| # | Section | Item | Status | Note |
|---|---------|------|--------|------|
| 1a | Title/Abstract | Identification as a randomised trial | ☐ | |
| 1b | Title/Abstract | Structured summary of trial design, methods, results, and conclusions | ☐ | |
| 2 | Open science | Trial registry name, identifying number (with URL), and date of registration | ☐ | use the `method-prereg` skill |
| 3 | Open science | Where the trial protocol and statistical analysis plan can be accessed | ☐ | link the `method-plan` SAP |
| 4 | Open science | Where and how de-identified participant data (with data dictionary), statistical code, and other materials can be accessed | ☐ | |
| 5a | Open science | Sources of funding and other support, and role of funders in design, conduct, analysis, and reporting | ☐ | |
| 5b | Open science | Financial and other conflicts of interest of the manuscript authors | ☐ | |
| 6 | Introduction | Scientific background and rationale | ☐ | |
| 7 | Introduction | Specific objectives related to benefits and harms | ☐ | |
| 8 | Methods | Patient or public involvement in the design, conduct, and reporting of the trial | ☐ | |
| 9 | Methods | Trial design: type of trial, allocation ratio, and framework (superiority, equivalence, non-inferiority, exploratory) | ☐ | |
| 10 | Methods | Important changes to the trial after it commenced, including outcomes or analyses not prespecified, with reasons | ☐ | Use the canonical `method-plan` SAP amendment log |
| 11 | Methods | Settings and locations where the trial was conducted | ☐ | |
| 12a | Methods | Eligibility criteria for participants | ☐ | |
| 12b | Methods | If applicable, eligibility criteria for sites and for individuals delivering the interventions | ☐ | |
| 13 | Methods | Intervention and comparator with sufficient detail to allow replication, and where any additional materials can be accessed | ☐ | |
| 14 | Methods | Prespecified primary and secondary outcomes, with measurement variable, analysis metric, aggregation method, and time point | ☐ | SAP-3 |
| 15 | Methods | How harms were defined and assessed | ☐ | |
| 16a | Methods | How sample size was determined, including all assumptions supporting the calculation | ☐ | use the `method-power` skill output |
| 16b | Methods | Explanation of any interim analyses and stopping guidelines | ☐ | |
| 17a | Methods | Who generated the random allocation sequence and the method used | ☐ | |
| 17b | Methods | Type of randomisation and details of any restriction (stratification, blocking, block size) | ☐ | |
| 18 | Methods | Mechanism used to implement the random allocation sequence and steps to conceal it until assignment | ☐ | |
| 19 | Methods | Whether personnel who enrolled and assigned participants had access to the allocation sequence | ☐ | |
| 20a | Methods | Who was blinded after assignment to interventions | ☐ | |
| 20b | Methods | If blinded, how blinding was achieved and similarity of interventions | ☐ | |
| 21a | Methods | Statistical methods used to compare groups for primary and secondary outcomes, including harms | ☐ | SAP-4 |
| 21b | Methods | Definition of who is included in each analysis, and in which group | ☐ | |
| 21c | Methods | How missing data were handled in the analysis | ☐ | |
| 21d | Methods | Methods for additional analyses (subgroup, sensitivity), distinguishing prespecified from post hoc | ☐ | |
| 22a | Results | For each group, numbers randomly assigned, receiving intended intervention, and analysed for the primary outcome (flow diagram) | ☐ | |
| 22b | Results | For each group, losses and exclusions after randomisation, with reasons | ☐ | |
| 23a | Results | Dates defining recruitment and follow-up periods for outcomes of benefits and harms | ☐ | |
| 23b | Results | If relevant, why the trial ended or was stopped | ☐ | |
| 24a | Results | Intervention and comparator as actually administered (who delivered, adherence, fidelity) | ☐ | |
| 24b | Results | Concomitant care received during the trial for each group | ☐ | |
| 25 | Results | Baseline demographic and clinical characteristics for each group | ☐ | |
| 26 | Results | For each outcome by group: number analysed, number with data at the time point, results with effect size and precision; absolute and relative effects for binary outcomes | ☐ | |
| 27 | Results | All harms or unintended events in each group | ☐ | |
| 28 | Results | Any other analyses performed (subgroup, sensitivity), distinguishing prespecified from post hoc | ☐ | |
| 29 | Discussion | Interpretation consistent with results, balancing benefits and harms, and considering other evidence | ☐ | |
| 30 | Discussion | Trial limitations: sources of bias, imprecision, generalisability, and multiplicity if relevant | ☐ | |
Related skills
| Skill | Stars | Updated | Works with | Status | Install |
|---|---|---|---|---|---|
| slack-gif-creatoranthropics/skillsKnowledge and utilities for creating animated GIFs optimized for Slack. Provides constraints, validation tools, and animation concepts. Use when users request animated GIFs for Slack like "make me a GIF of X doing Y for Slack." | Stars: 198k | Updated | Claude CodeCodex | Verified | Install |
| ponytailDietrichGebert/ponytailLazy senior dev mode for any coding task: the smallest change that fully solves it, and a reply a busy human understands in one read. | Stars: 196k | Updated | Claude CodeCodex | Verified | Install |
| ponytail-debtDietrichGebert/ponytailHarvest every shortcut: comment into one debt ledger, so deferrals get tracked instead of forgotten. One-shot report. | Stars: 196k | Updated | Claude CodeCodex | Verified | Install |
| ponytail-debtDietrichGebert/ponytailList every `shortcut:` comment (and older `ponytail:` ones) as a debt ledger. One-shot report, changes nothing. Use for "ponytail debt", "what did ponytail defer", "list the shortcuts", /ponytail-debt. | Stars: 196k | Updated | Claude CodeCodex | Verified | Install |